Opdivo (Nivolumab) vs Braftovi (encorafenib)

Opdivo (nivolumab) is an immune checkpoint inhibitor that works by blocking the PD-1 protein on T cells, thereby enhancing the immune system's ability to attack cancer cells. Braftovi (encorafenib) is a targeted therapy that inhibits the activity of certain mutations of the BRAF protein, which can promote cancer cell growth in melanoma and other cancers. The choice between Opdivo and Braftovi would depend on the specific type of cancer, its molecular profile, and the presence of a BRAF mutation, among other factors, and should be made in consultation with an oncologist.

Difference between Opdivo and Braftovi

Metric	Opdivo (Nivolumab)	Braftovi (encorafenib)
Generic name	Nivolumab	Encorafenib
Indications	Various types of cancers including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and more.	Used in combination with other drugs for the treatment of patients with metastatic melanoma with a BRAF V600E or V600K mutation.
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody, which enhances the immune system's ability to fight cancer.	BRAF inhibitor, which works by targeting and inhibiting the BRAF protein in cancer cells with a mutation in the BRAF gene.
Brand names	Opdivo	Braftovi
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, weakness, cough, dyspnea, constipation, decreased appetite, back pain, joint pain, upper respiratory tract infection.	Fatigue, nausea, vomiting, abdominal pain, arthralgia, rash, anemia, increased creatine phosphokinase, decreased appetite, hemorrhage, diarrhea, hypertension, headache, and peripheral neuropathy.
Contraindications	Patients with severe hypersensitivity to nivolumab or any of its excipients.	Patients with severe hypersensitivity to encorafenib or any of its excipients.
Drug class	Immune checkpoint inhibitor	BRAF kinase inhibitor
Manufacturer	Bristol-Myers Squibb	Pfizer (acquired Array BioPharma)

Efficacy

Efficacy of Opdivo (Nivolumab) in Colorectal Cancer

Opdivo, also known as Nivolumab, is a programmed death receptor-1 (PD-1) blocking antibody used in cancer immunotherapy. In colorectal cancer, its efficacy is particularly noted in patients with DNA mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). These biomarkers indicate a higher likelihood of response to immunotherapy. Clinical trials have demonstrated that Nivolumab can lead to significant survival benefits in this subset of colorectal cancer patients. It is often used after standard chemotherapy has failed, and its efficacy in this context has led to its approval for this indication.

Efficacy of Braftovi (Encorafenib) in Colorectal Cancer

Braftovi, known generically as encorafenib, is a BRAF inhibitor that has shown efficacy in the treatment of colorectal cancer with a specific genetic profile. It is most effective in patients whose tumors harbor a mutation in the BRAF V600E gene. When used in combination with other targeted therapies, such as anti-EGFR antibodies or MEK inhibitors, Braftovi has been shown to improve overall survival and progression-free survival compared to standard care. The combination of Braftovi with other agents represents a significant advancement in the treatment of BRAF-mutant colorectal cancer, which is historically associated with a poor prognosis.

Combination Therapy Involving Opdivo and Braftovi

Recent research has explored the potential of combining Opdivo and Braftovi, along with other agents, for the treatment of colorectal cancer. This combination aims to target the cancer through different mechanisms: immunotherapy and targeted therapy against specific mutations. While studies are ongoing, preliminary data suggest that such combination therapies can lead to improved outcomes in patients with specific molecular profiles. However, the efficacy of these combinations can vary, and further research is necessary to fully understand the best use of these drugs together.

Conclusion

In conclusion, both Opdivo (Nivolumab) and Braftovi (Encorafenib) have shown efficacy in the treatment of colorectal cancer, but their effectiveness is highly dependent on the genetic makeup of the tumor. Opdivo is particularly effective in patients with dMMR or MSI-H colorectal cancer, while Braftovi is beneficial for those with BRAF V600E mutations. The possibility of combining these drugs with other therapies offers hope for improved treatment outcomes, but further clinical trials are essential to optimize their use. As with all cancer treatments, the efficacy of these medications must be evaluated on a case-by-case basis, taking into account the unique characteristics of each patient's disease.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Braftovi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Opdivo or Braftovi today

If Opdivo or Braftovi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Braftovi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: